太极集团有限公司（简称“太极集团”，股票代码：600129）始建于1972年，2021年完成战略重组，成为“世界500强”中国医药集团有限公司的控股企业。公司以现代中药智能制造为主、麻精特色化药为辅，作为国药集团现代中药板块的重要组成部分，致力于传承创新中医药和发展现代医药，有13家制药厂、20多家医药商业公司，另有以川渝为主阵地的3000多家连锁药房，业务涵盖医药研发、药品生产、医药商业、中药材资源等领域，员工1.3万人。
公司连续获评工信部“中国医药工业百强企业”；2016年获“国家知识产权示范企业”称号；在国际权威品牌价值咨询公司Brand Finance发布的2023年中国医药品牌价值排名中位列13位；公司通过了国家工信部“工业化和信息化两化融合管理体系”认证；公司中药提取中心通过国家工信部医药产业数字化项目技术评审；公司旗下两大连锁药房品牌“桐君阁大药房”和“太极大药房”多次荣获“中国商业名牌企业”、“中国连锁药店直营力百强企业”，在2019-2020年度《中国药店》价值榜100强中排名第六，综合实力100强中排名第八；公司获评“2023年度中国非处方药生产企业综合统计”第二名；2022年3月获批重庆首个“国家中医药服务出口基地”。
1998年，太极集团与国内外多家院校合作建立国家首批博士后工作站；1999年，太极集团技术中心被认定为国家企业技术中心。近年来承担国家科技部、发改委、工信部等重大专项项目近40项、省级项目50余项。公司成功研发新药40余个、获国家新药证书30余个、曾获中国专利金奖3项。拥有有效授权专利300件，药品批文共计1240个，其中中药品种批文690个、化药品种批文550个，医保品种739个、基药369个。
公司产品涉及六大治疗领域，主要有以藿香正气口服液、太罗等为代表的消化系统及代谢用药，以急支糖浆为代表的呼吸系统用药，以丹参口服液为代表的心血管用药，以益保世灵为代表的抗感染药物，以通天口服液、美菲康为代表的神经系统用药，以紫杉醇、补肾益寿胶囊等为代表的抗肿瘤及免疫调节药物等，以及大健康养生产品。公司产品拥有较高的市场占有率，其品牌、品质赢得了老百姓的认可和信赖。
医药工业
中药生产方面，拥有中华老字号“桐君阁”“剑门”和“桐君阁传统丸剂制作技艺”“太极五子衍宗丸制作技艺”等多项国家级、省市区级非物质文化遗产，拥有年产1亿瓶的糖浆剂生产线、年产30亿支的口服液生产线、年提取药材10万吨的中药材前处理车间和提取浓缩车间。化药生产方面，拥有西南地区麻醉药及精神类药品定点生产企业，具有先进的缓控释技术、速释技术、滴丸和缓释滴丸等技术。中药饮片生产方面，拥有年产优质中药饮片1500吨的智能化工厂。
医药商业
公司成功打造了集医药零售、医院销售、零售终端配送、商业分销、医药进出口、医药电商、中药经营、医药三方物流等多业态为一体的大型医药商业体系，经营品规达5万余个。零售业务凭借诚信的经营理念、优质和专业的服务赢得了大众的信赖，综合竞争力在川渝位居前列。公司设立有多个配送中心，总仓储面积约15万平方米，具备自有冷链配送、厢式配送车200余辆，配送能力辐射终端10万家以上。公司旗下桐君阁股份有限公司是重庆市医药物资战略储备单位，其合作配送单位——桐君阁物流配送有限公司，是重庆市首家拥有医药、器械三方物流双资质的企业，设计仓容100万件，年吞吐能力达2000万件。
中药资源
以优质中药材为导向，坚持“道地种植、全程追溯”理念，遵循“三无一全”、“六统一”要求，通过“太极中药农业全程质量追溯平台”全过程管控药材质量，已建成中药材规范化种植基地10多万亩。半夏、金荞麦、前胡等单品种植规模行业领先。承担国家级中药材种植与科研项目5个，省级科技攻关项目8个。公司多次被评为“农业产业化国家重点龙头企业”。
国际业务
紧跟“一带一路”步伐，积极开拓中医药海外市场，弘扬中医药文化。太极藿香正气口服液、急支糖浆、补肾益寿胶囊、太极天胶、丹参口服液、穿龙骨刺片、超浓缩六味地黄丸等系列太极产品共计30个品规，已在新加坡、马来西亚、印度尼西亚、泰国、美国、加拿大、俄罗斯、巴基斯坦等几十个国家和地区注册，获注册文号100余个。
大健康产业
太极集团积极落实“健康中国”战略，加快大健康产业步伐，将中医药文化与生态养生相结合，打造大健康产品及全新生态康养项目。拥有“TAIJI”乌发露、沐浴露、番茄红素软胶囊等大健康产品，并通过太极医疗养生产业基地（国药集团国际生命健康城）、武陵山国家森林公园、康定虫草基地等多个新理念康养项目逐步构建大健康产业链新格局。
初心如磐，骏业日新。
太极集团将秉承“关爱生命 呵护健康”的企业理念，心怀“国药泽华夏，太极济苍生”的初心使命，紧跟国药集团“四梁八柱、百强万亿”创新驱动型全生命周期、全产业链和全生态圈的总体发展战略，遵循“做强做优做大医药健康主业”的目标定位，正源出新、精益求精，不断推进中医药现代化，努力打造世界一流的中药企业，推动中医药走向世界，为建设健康中国、实现中华民族伟大复兴的中国梦贡献国药太极力量！
About Us
In 2021, Taiji Group Co., Ltd. (Taiji Group for short, stock code: 600129), whose history could be dated back to 1972, accomplished a strategic restructuring, becoming a member of China National Pharmaceutical Group Co., Ltd.(Sinopharm for short), one of the Fortune Global 500 company.
Taiji Group mainly engages in the intelligent manufacturing of modern Chinese medicine, supplemented by stupefacient and psychotropic drugs. As an important part of Sinopharm's modern Chinese medicine division, Taiji Group is committed to the inheritance and innovation of traditional Chinese medicine and the development of modern Chinese medicine.
Taiji Group owns 13 pharmaceutical factories, more than 20 pharmaceutical commercial companies, two pharmaceutical research institutes, more than 3,000 chain pharmacies mainly based in Sichuan and Chongqing，with 13,000 employees and a full chain mainly covering pharmaceutical research and development, industrial production, pharmaceutical sales and big health industry.
Taiji Group has been consecutively rated as a "Top 100 Pharmaceutical Enterprise in China" by the Ministry of Industry and Information Technology. In 2016, Taiji Group won the title of "National Intellectual Property Model Enterprise". In the China Pharmaceutical Brand Value Ranking 2023 released by Brand Finance, an authoritative international brand value consulting company, Taiji Group ranked 13th. Taiji Group has earned the "Industrialization-Informatization Integration Management System" certification by the Ministry of Industry and Information Technology. The TCM Extraction Center has passed the technical review by the Ministry of Industry and Information Technology as a pharmaceutical industry digitization project.
Two chain pharmacy brands “TongJunGe Pharmacy” and “Taiji Pharmacy” have won titles of “China's Famous Commercial Enterprise” and “Top 100 Chain Pharmacy in China by Direct Sales Strength” several times， ranking 6th in the Top 100 Value List and ranking 8th in the Top 100 Comprehensive Strength List of 《China Drug Store》 in 2019-2020 . Taiji Group won second place in the "Comprehensive Statistics of China's OTC Drug Manufacturers in 2023". In March 2022, Taiji Group was approved as the first "National TCM Service Export Base" in Chongqing.
In 1998, Taiji Group worked with domestic and foreign universities to establish the first batch of post-doctoral workstations in China. In 1999, Taiji Group’s Technology Center was recognized as a National Enterprise Technology Center. In recent years, Taiji Group has undertaken nearly 40 major special projects of the Ministry of Science and Technology, the National Development and Reform Commission and the Ministry of Industry and Information Technology, and more than 50 provincial projects. Taiji Group has successfully developed more than 40 new drugs, obtained more than 30 national new drug certificates, and won 3 China Patent Gold Awards. Taiji Group holds 300 valid authorized patents and a total of 1,240 drug approvals, including 690 approvals for TCM drugs, 550 approvals for chemical drugs, 739 approvals for drugs covered by medical insurance, and 369 approvals for essential drugs.
Taiji products cover six therapeutic areas, including digestive system and metabolic system drugs represented by Huo Xiang Zheng Qi Kou Fu Ye and Rosiglitazone Sodium Tablets; Respiratory system drugs represented by Ji Zhi Tang Jiang; Cardiovascular drugs represented by Dan Shen Kou Fu Ye；Anti-infective drugs represented by Ceftizoxime Sodium for Injection；Nervous system drugs represented by Tong Tian Kou Fu Ye and Morphine Hydrochloride Sustained-Release Tablets；Antitumor and immunomodulatory drugs represented by Paclitaxel Injection and Bu Shen Yi Shou Jiao Nang, as well as health products. Taiji products have a high market share. The brand and quality have won people's recognition and trust.
Pharmaceutical Manufacturing
In terms of TCM production, Taiji Group owns China Time-Honored Brand "TongJunGe", and a number of national, provincial, municipal, district items of intangible cultural heritage such as the "TongJunGe traditional pill production technique", in addition to a syrup production line with an annual output of 100 million bottles, an oral solution production line with an annual output of 2 billion bottles, a TCM material pre-treatment workshop and extraction and concentration workshop with an annual output of 100,000 tons. In terms of chemical drug production, Taiji Group owns a designated manufacturer of stupefacient and psychotropic drugs in southwest China, which has advanced controlled slow release technology, rapid release technology, guttate pill and slow release guttate pill technologies. In terms of TCM decoction pieces production, we have an intelligent factory with an annual output of 1,500 tons of high-quality TCM decoction pieces.
Pharmaceutical Sales
Taiji Group has successfully built a large pharmaceutical sales system integrating pharmaceutical retail, hospital sales, retail terminal distribution, commercial distribution, pharmaceutical import and export, pharmaceutical e-commerce, TCM sales, 3rd-party pharmaceutical logistics and other services for more than 50,000 product specifications. By virtue of integrity, high quality and professional service, the retail business has won the trust of the public, with comprehensive competitiveness among the top drug vendors in Sichuan and Chongqing. Taiji Group has set up a number of distribution centers, with a total storage area of about 150,000 square meters, more than 200 vehicles for distribution and cold chain distribution. The distribution capacity reaches more than 100,000 terminals. Taiji Group’s subsidiary such as Tong Jun Ge Co., Ltd., is a strategic reserve unit for medical supplies in Chongqing; Tong Jun Ge Logistics & Distribution Co., Ltd., is the first qualified 3rd-party logistics enterprise for medicine and medical instruments in Chongqing, with a designed warehouse capacity of 1 million pieces and an annual throughput capacity of 20 million pieces.
TCM Resources
Focusing on high-quality TCM materials, Taiji Group insists on “genuine planting, full traceability”, follow the requirements of “sulfur-free, aflatoxin-free, pollution-free, whole-process traceability” and “six unification”, and control the quality of TCM materials throughout the production process through "Taiji TCM Agriculture Full Quality Traceability Platform". Taiji Group has built more than 100,000 mu of standard planting bases for TCM materials. The planting scale of Pinellia ternata, Fagopyrum cymosum, Radix Peucedani and other single varieties is leading in the industry. We have undertaken 5 national TCM material planting and scientific research projects and 8 provincial key scientific and technological research projects. Our company has been rated as a "National Key Leading Enterprise for Agricultural Industrialization" for several times.
International Business
Closely following the Belt and Road Initiative, Taiji Group actively explores overseas markets for TCM and promotes TCM culture. Taiji product series with 30 product specifications, including Huo Xiang Zheng Qi Kou Fu Ye、Ji Zhi Tang Jiang、Bu Shen Yi Shou Jiao Nang、Taiji E Jiao、Dan Shen Kou Fu Ye、Chuan Long Gu Ci Pian、Liu Wei Di Huang Wan (Concentrated Pills), have been registered in dozens of countries and territories, such as Singapore, Malaysia, Indonesia, Thailand, the United States, Canada, Russia, Pakistan, with 100 registration numbers.
Big Health Industry
Taiji Group actively implements the "Healthy China" strategy, speeds up its pace in the big health industry, combines TCM culture with ecological health preservation, and creates health products and new ecological health care projects. Taiji health products include “TAIJI”Shampoo,“TAIJI”Shower Gel, Lycopene Soft Capsule and so on. We are forming a new pattern in the big health industry chain through a number of new concept health care projects, such as Taiji Health Care Industry Base (Sinopharm International Life and Health City), Wuling Mountain National Forest Park and Kangding Cordyceps Base.
Unshaken Original Aspiration, Constant Business Progress
Guided by the core value of “All for Health,Health for All”, Taiji Group keeps the original aspiration of “TCM for Huaxia, Taiji for People” in mind, follows Sinopharm's overall development strategy of innovation-driven full life cycle, full industry chain and full ecosystem with "four beams and eight pillars, top 100 + 100 trillion", stick to the target position of "stronger, better and bigger pharmaceutical and health core business". Taiji Group innovates on heritage, seek for greater perfection, constantly promote the modernization of TCM, strives to build a world-class TCM enterprise, promote the internationalization of TCM., and contributes to the building of a healthy China and the realization of the Chinese dream of the great rejuvenation of the Chinese nation.
